Ona Therapeutics

Executive Summary

Ona Therapeutics is a privately held Spanish biotechnology company founded in 2019 and based in Barcelona, dedicated to developing first-in-class antibody-drug conjugates (ADCs) for the treatment of metastatic and treatment-refractory cancers. Leveraging privileged biology derived from unique insights into advanced cancer patients, Ona partners with leading academics and clinicians to identify novel therapeutic targets. The company's expertise in biologics enables the design of ADCs and antibody therapies that aim to address significant unmet medical needs in oncology. Currently in the pre-clinical stage, Ona has not yet disclosed total funding or valuation, but its focused strategy on metastasis distinguishes it in the competitive ADC landscape.

Upcoming Catalysts (preview)

• Q4 2027Lead ADC program IND filing or first-in-human clinical trial initiation30% success
• Q2 2027Presentation of preclinical efficacy data at a major oncology conference (e.g., AACR or ASCO)70% success
• Q1 2027Announcement of strategic partnership or Series A/B financing round50% success